<DOC>
	<DOCNO>NCT02949024</DOCNO>
	<brief_summary>This study design demonstrate safety tolerability suprachoroidal CLS-TA alone combination intravitreal aflibercept subject diabetic macular edema associate diabetes mellitus .</brief_summary>
	<brief_title>Suprachoroidal Injection CLS-TA Alone With Aflibercept Subjects With Diabetic Macular Edema</brief_title>
	<detailed_description>This Phase 1/2 , multicenter , open-label study subject DME associate diabetes mellitus . Subjects screen eligible , assign study arm Baseline Visit ( Visit 1 , Day 0 ) . Following Baseline Visit , subject participate six month follow-up visit ( Visit 2-7 ; Weeks 4-24 ) safety efficacy assessment determine whether additional therapy need base upon establish criterion .</detailed_description>
	<mesh_term>Macular Edema</mesh_term>
	<mesh_term>Edema</mesh_term>
	<mesh_term>Triamcinolone hexacetonide</mesh_term>
	<mesh_term>Triamcinolone Acetonide</mesh_term>
	<mesh_term>Triamcinolone</mesh_term>
	<mesh_term>Triamcinolone diacetate</mesh_term>
	<criteria>Men woman ≥ 18 year age type 1 type 2 diabetes mellitus DME central involvement study eye ETDRS BCVA letter score 83 14 , inclusive ( Snellen equivalent 20/25 20/500 ) study eye Intraocular pressure ≥ 22 mmHg uncontrolled glaucoma ( open angle angle closure ) study eye History previous ophthalmic surgery study eye within 90 day screen Subjects previously treat DME treat study eye intravitreal injection antiVEGF periocular corticosteroid within 90 day prior screen ( Previous TX arm ) Subjects previously treat DME treat study eye intraocular corticosteroid within 6 month prior screen ( Previous TX arm )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Diabetes mellitus</keyword>
	<keyword>Diabetic retinopathy</keyword>
	<keyword>Microneedle</keyword>
	<keyword>Microinjection</keyword>
	<keyword>Triamcinolone</keyword>
	<keyword>Choroid</keyword>
	<keyword>Choroid Injection</keyword>
	<keyword>Aflibercept</keyword>
	<keyword>Suprachoroidal</keyword>
</DOC>